Clinigen Group PLC (LON:CLIN) Insider Acquires £41,600 in Stock

Clinigen Group PLC (LON:CLIN) insider Shaun Edward Chilton acquired 10,000 shares of the firm’s stock in a transaction on Monday, March 23rd. The stock was bought at an average price of GBX 416 ($5.47) per share, with a total value of £41,600 ($54,722.44).

LON:CLIN opened at GBX 478.40 ($6.29) on Friday. The company has a debt-to-equity ratio of 82.15, a current ratio of 1.12 and a quick ratio of 0.86. The firm has a market cap of $635.55 million and a price-to-earnings ratio of 46.00. The firm’s fifty day moving average price is GBX 724.83 and its 200 day moving average price is GBX 847.21. Clinigen Group PLC has a 1-year low of GBX 600.50 ($7.90) and a 1-year high of GBX 1,069 ($14.06).

Clinigen Group (LON:CLIN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported GBX 30.80 ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of GBX 31 ($0.41) by GBX (0.20) ($0.00). As a group, analysts expect that Clinigen Group PLC will post 2573.0001139 earnings per share for the current fiscal year.

The company also recently declared a dividend, which will be paid on Friday, April 17th. Stockholders of record on Thursday, March 19th will be paid a dividend of GBX 2.15 ($0.03) per share. The ex-dividend date of this dividend is Thursday, March 19th. This represents a dividend yield of 0.29%. Clinigen Group’s dividend payout ratio (DPR) is 0.67%.

CLIN has been the topic of a number of research reports. Peel Hunt reissued a “buy” rating on shares of Clinigen Group in a report on Thursday, March 5th. Liberum Capital reaffirmed a “buy” rating on shares of Clinigen Group in a research note on Tuesday. Finally, Royal Bank of Canada reaffirmed a “top pick” rating and set a GBX 1,500 ($19.73) price objective (down from GBX 1,600 ($21.05)) on shares of Clinigen Group in a research note on Friday, March 20th.

About Clinigen Group

Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.

Read More: Understanding dividend yield and dividend payout ratio

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with's FREE daily email newsletter.